Keys to success for in-house lentiviral vector tech transfer and manufacture

Published: 29 April 2021
Interview
Nicole Nuñez,
Nicole Nuñez
Regulatory Scientist, Eureka Therapeutics
Nicole Nuñez, PhD, joined Eureka Therapeutics in 2018 as a Process Development Scientist, and co-led the process development, manufacture, tech transfer, vendor management and regulatory compliance of lentiviral vectors to be used in the production of T-cell based therapies. Nicole currently serves Eureka as a Regulatory Scientist focusing on the development and implementation of regulatory strategy for the company’s T-cell therapy and vector products.
Liam Powers
Liam Powers
Process Development Research Associate, Eureka Therapeutics
Liam Powers joined Eureka Therapeutics as an intern in 2016 and is currently a Process Development Research Associate. His main focus has been the optimization and development of lentiviral vector production and purification systems. He led the engineering of Eureka’s GMP vector process and provided oversight in tech transfer and manufacturing operations.

Nicole Nuñez, PhD, joined Eureka Therapeutics in 2018 as a Process Development Scientist, and co-led the process development, manufacture, tech transfer, vendor management and regulatory compliance of lentiviral vectors to be used in the production of T-cell based therapies. Nicole currently serves Eureka as a Regulatory Scientist focusing on the development and implementation of regulatory strategy for the company’s T-cell therapy and vector products.

Liam Powers joined Eureka Therapeutics as an intern in 2016 and is currently a Process Development Research Associate. His main focus has been the optimization and development of lentiviral vector production and purification systems. He led the engineering of Eureka’s GMP vector process and provided oversight in tech transfer and manufacturing operations.

Read now